![]() |
|
|
Vol. 289, Issue 3, 1509-1516, June 1999
Department of Physiology and Pharmacology (J.A.C.), College of
Veterinary Medicine, University of Georgia, Athens, Georgia and
Department of Medicine; and Department of Biochemistry and Molecular
Pharmacology (N.M.B., A.B.M., L.L.S.), Jefferson Medical College,
Philadelphia, Pennsylvania
Botulinum toxin blocks transmitter release by proceeding through a
series of four steps: binding to cell surface receptors, penetration of
the cell membrane by receptor-mediated endocytosis, penetration of the
endosome membrane by pH-induced translocation, and intracellular
proteolysis of substrates that govern exocytosis. Each of these steps
is essential for toxin action on intact cells. Therefore, alterations
in cell structure or cell function that impede any of these steps
should confer resistance to toxin. In the present study, screening for
susceptibility to four serotypes of botulinum toxin revealed that the
cutaneous-pectoris nerve-muscle preparation of Rana
pipiens is resistant to type B botulinum toxin. Resistance was
demonstrated both by electrophysiologic techniques and by dye-staining
techniques. In addition, resistance to serotype B was demonstrated at
toxin concentrations that were 2 orders of magnitude higher than those
associated with blockade produced by other serotypes. In experiments on
broken cell preparations, type B toxin cleaved synaptobrevin from frog
brain synaptosomes. However, the toxin did not bind to frog nerve
membranes. These findings suggest that resistance is due to an absence
of cell surface receptors for botulinum toxin type B. The fact that
cutaneous-pectoris preparations were sensitive to other botulinum toxin
serotypes (A, C, and D), as well as other neuromuscular blocking agents (
-latrotoxin,
-bungarotoxin), indicates that botulinum toxin type
B receptors are distinct.
This article has been cited by other articles:
![]() |
S. Kalandakanond and J. A. Coffield Cleavage of Intracellular Substrates of Botulinum Toxins A, C, and D in a Mammalian Target Tissue J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 749 - 755. [Abstract] [Full Text] |
||||
![]() |
S. Kalandakanond and J. A. Coffield Cleavage of SNAP-25 by Botulinum Toxin Type A Requires Receptor-Mediated Endocytosis, pH-Dependent Translocation, and Zinc J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 980 - 986. [Abstract] [Full Text] |
||||